Hani Gabra

Founder presso Papyrus Therapeutics, Inc.

Health Technology

Consumer Services

Commercial Services

Profilo

Hani Gabra is the founder of Papyrus Therapeutics, Inc. He is currently a Professor at Imperial College London.
He previously worked as the Director of Clinical Development at BerGenBio ASA from 2021 to 2022 and as the Vice President of Early Clinical Development at AstraZeneca PLC.

Posizioni attive di Hani Gabra

Società	Posizione	Inizio
Imperial College London	Corporate Officer/Principal	-
Papyrus Therapeutics, Inc. Papyrus Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Papyrus Therapeutics, Inc. is a preclinical stage biopharma American company that focuses on developing cancer therapeutics based on a novel target, opioid-binding cell adhesion molecule (OPCML). Papyrus Therapeutics is based in Oxford, UK. The company's expertise in this target is based on years of research and multiple publications by the company's co-founder and chief scientific adviser, Professor Hani Gabra. The company was founded by Paul Blake and Hani Gabra, and Paul Blake has been the CEO since incorporation.	Founder	-

Tutte le posizioni attive di Hani Gabra

Precedenti posizioni note di Hani Gabra

Società	Posizione	Fine
BERGENBIO ASA	Chief Tech/Sci/R&D Officer	-
ASTRAZENECA PLC	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Hani Gabra

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Hani Gabra

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
ASTRAZENECA PLC	Health Technology
BERGENBIO ASA	Health Technology

Aziende private	1
Papyrus Therapeutics, Inc. Papyrus Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Papyrus Therapeutics, Inc. is a preclinical stage biopharma American company that focuses on developing cancer therapeutics based on a novel target, opioid-binding cell adhesion molecule (OPCML). Papyrus Therapeutics is based in Oxford, UK. The company's expertise in this target is based on years of research and multiple publications by the company's co-founder and chief scientific adviser, Professor Hani Gabra. The company was founded by Paul Blake and Hani Gabra, and Paul Blake has been the CEO since incorporation.	Commercial Services